Introduction
============

Myeloid sarcoma (MS), also known as granulocytic sarcoma or chloroma, is a rare clinical condition characterized by aggregation of immature myeloid cells presenting as an extramedullary mass \[[@B1]\]. The most commonly involved sites are the small intestine, bone, skin, and lymph nodes \[[@B2]\]. MS can develop de novo or emerge during the clinical course of acute myeloid leukemia (AML), myeloproliferative disorder (MPD), or myelodysplastic syndrome (MDS). In AML patients, MS might represent the first manifestation of AML, predating it by months or years. It can also be the initial presentation of relapse in remission, with or without underlying bone marrow (BM) relapse, with reported incidence of 3-9% \[[@B3],[@B4]\].

MS can present at various sites of the body resulting in prominent symptoms and signs. Diagnosis of MS requires a high degree of vigilance by physicians. Its optimal treatment remains controversial. Chemotherapy or hematopoietic cell transplantation is often considered the frontline treatment for MS. Radiotherapy (RT) could be reserved for palliation of symptomatic or rapidly progressive lesions \[[@B5],[@B6]\] or as part of a combined modality treatment in conjunction with chemotherapy or hematopoietic cell transplantation. RT is also considered a consolidative treatment for isolated MS without BM involvement, or during BM remission after systemic therapy \[[@B7]\]. However, data on outcome from RT in MS is limited and most previous studies are case series reports.

In this study, we investigated the possible underlying predictive factors, including clinicopathologic features and radiotherapeutic parameters, for response to RT in MS patients who received frontline or palliative RT. We evaluated 20 patients and their irradiated lesions, and reviewed responses to RT and RT doses reported in previous studies on MS patients who received frontline or palliative RT.

Patients and methods
--------------------

### Patients and clinical characteristics

Twenty consecutive patients with MS who received RT at our institute from 2000 to 2010 were retrospectively reviewed. This restrospective study was approved by institutional review board of National Taiwan University Hospital. Pathologic evaluation of incision biopsy or needle aspiration of these 20 patients demonstrated the histomorphologic features of MS characterized by homogenous malignant infiltrations of immature large cells with ovale and slightly nuclei. Further immunohistochemical studies, including lysozyme and myeloperoxidase (MPO), CD68, and chloroacetate, were used to detect their myeloid origins and exclude lymphoreticular tumors and mesenchymal tumors. The histopathological characteristics and immunohistochemical results of all tumor specimens were independently reviewed by experienced hematopathologists. Cytogenetic studies were also performed. The patients had 43 irradiated lesions. Clinicopathologic features including age, sex, underlying hematologic diseases, MS site for RT, timing of MS emergence, cytogenetics, and radiotherapeutic parameters (including RT dose and fractionation), and responses of the treated lesions to RT were assessed. During the same period, 18 MS patients without RT served as control group.

### Radiotherapy

RT was provided using ^60^Cobalt, 6--10 MV linear accelerators or 9--12 MeV electrons for superficial lesions. The RT field was the gross tumor and a 2--3 cm margin. Radiation doses ranged from 6 Gy to 35 Gy (median, 20 Gy) at a dose per fraction of 1.5-3.5 Gy (median, 2 Gy). Twenty-eight lesions (65.2%) received RT in doses ≥20 Gy. Because various fraction sizes were used, conversion of the total radiation dose to biologically equivalent doses (BED) delivered at 2 Gy per fraction (BED2) were calculated using the linear-quadratic model \[[@B6]\]:

$$\textit{BED}2\left( \textit{Gy} \right) = \frac{\mathit{nd}\left( {1 + \frac{\mathit{d}}{\mathit{\alpha}/\mathit{\beta}}} \right)}{\left( {1 + \frac{2}{\mathit{\alpha}/\mathit{\beta}}} \right)}$$

where n is the number of fractions and d is the dose (Gy) per fraction. An α/β ratio of 10 is used for leukemia \[[@B7]\], resulting in a BED2 ranging from 6.5 Gy to 35.9 Gy (median, 20 Gy).

Lesions' initial responses to RT were assessed by physical examination, computed tomography (CT), or magnetic resonance imaging (MRI) within 4 weeks of completion of RT. A complete response (CR) was defined as no evidence of disease and a partial response (PR) as \>50% regression of all measurable tumor mass. Lesions with \<50% regression, stable disease (SD), or progression were classified as displaying no response.

### Statistical analysis

Seven of the 20 patients received multiple courses of RT to distinct lesions, resulting in 43 irradiated lesions. Among 7 patients with multiple courses of RT, 2 patients received coinstantaneous irradiation to multiple sites and 5 patients received multiple sequential courses of RT. If a patient received multiple sequential courses of RT, data from the first RT course were used for analysis. Data from one RT site with coinstantaneous irradiations were randomly selected when patients concurrently received RT to multiple sites. Treatment responsesto RT doses (BED), underlying hematologic diseases, age, sex, cytogenetics, bone marrow transplant (BMT) prior to RT, and BM status at the time of RT in MS were correlated. Fisher's exact test was used to evaluate the associations between category variables. Crude odds ratios (OR), 95% confidence intervals (CI), and *P*-values were calculated using univariate logistic regression analysis. Post-RT overall survival (OS) was calculated using the Kaplan-Meier method.

The Generalized Estimating Equation(GEE) was introduced by Zeger and Liang \[[@B8]\] to cope with clustering data that would otherwise be analyzed using a generalized linear model. GEE has become an essential tool for the analysis of correlated data. In this study, GEE was used to account for correlations in responses to RT among lesions from the same patient. The unit of analysis was the irradiated lesion. All statistical analysis was performed using SAS software (9.2, SAS Institute Cary, NC).

Results
=======

Clinicopathologic features and survival of MS patients with RT
--------------------------------------------------------------

We included 20 patients (median age, 45 years old (y), range 4--83 y; 10 men and 10 women) with 43 irradiated lesions in our analyses. The median follow-up time was 4.3 months (range, 0.5-56.7 months). Table  [1](#T1){ref-type="table"} displays the clinicopathologic features of the patients and their treated lesions. The underlying hematologic diseases included AML in 14 (70%) patients, chronic myeloid leukemia (CML) in 4 (20%) patients, MDS with AML transformation in one (5%) patient, and de novo MS in one (5%) patient. Of the 14 AML patients, 6 (42.9%) were French-American-British (FAB) M2, 5 (35.7%) were FAB M1, 2 (14.3%) were FAB M4, and one (7.1%) was FAB M5. The irradiated lesions in the 20 patients included 23 (53.5%) skin, 4 (9.3%) breast, 4 (9.3%) brain parenchyma, 3 (7%) spinal cord, and 3 (7%) bone lesions, plus one (2.3%) anal, one (2.3%) cervical, one (2.3%) pituitary, one (2.3%) paranasal sinus, one (2.3%) buccal mucosal, and one (2.3%) nipple lesion.

###### 

Patient characteristics for MS patients with RT

  **Patient no.**   **Age**   **Gender**   **Underlying disease**   **GS site for radiotherapy**   **Timing of GS emergence**                                      **Cytogenetics**
  ----------------- --------- ------------ ------------------------ ------------------------------ --------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------
  1                 62        F            AML-M2                   Skin                           Relapse after chemotherapy, BM also (+)                         Normal
  2                 50        M            CML                      Anus                           CML in blast crisis                                             47 XXY, inv(11)
  3                 83        M            AML-M4                   Skin                           Found at initial presentation with BM (+)                       t(2;14), NPM(-), FLT3(-)
  4                 55        M            AML-M1                   Spinal cord                    Relapse after chemotherapy, BM also (+)                         t(9;22) Philadelphia chromosome (+)
  5                 58        M            AML-M1                   Skin (7 lesions)               Relapse after BMT, BM also (+)                                  Normal
  6                 6         F            CML                      Bone (right femur)             CML in blast crisis                                             t(9;22) Philadelphia chromosome (+)
  7                 71        F            MDS- RAEB 2              Brain                          \-                                                              Normal
  8                 41        F            AML-M2                   Cervix                         Relapse after BMT, BM (-)                                       t(8;21)
                                                                    Right breast                   Relapse after BMT, BM (-)                                        
  9                 42        M            *de novo* sarcoma        Right nipple                   Found at presentation, BM (-)                                   Normal
                                                                    Brain                          Relapse after chemotherapy, BM also (+)                          
                                                                    Paranasosinus                  Relapse after chemotherapy, BM also (+)                          
  10                56        M            CML                      Spinal cord                    CML in blast crisis                                             Normal
  11                22        M            AML-M4                   Skin (11 lesions)              Relapse after BMT, BM (-)                                       del(1)(p32p36), t(10;11)(p13;q13)
  12                44        F            CML                      Right breast                   CML in blast crisis receiving BMT. relapse after BMT, BM (-)    Normal
  13                75        F            AML-M2                   Skin                           Found at initial presentation with BM (+)                       del(15)(q22q35)
  14                29        F            AML-M2                   Pituitary gland                Relapse after BMT, BM (-)                                       Normal
  15                32        F            AML-M1                   Right breast                   Relapse after BMT, BM (-)                                       Normal
                                                                    Left breast                    Relapse after BMT, BM (-)                                        
  16                47        M            AML-M1                   Brain                          Relapse after chemotherapy, BM also (+)                         Normal
                                                                    Spinal cord                    Relapse after chemotherapy, BM also (+)                          
  17                47        F            AML-M2                   Skin                           Relapse after chemotherapy, BM also (+)                         t(8;21)
  18                40        M            AML-M5                   Skin                           Emerging during chemotherapy and persistent after BMT, BM (+)   -3p,t(5;17)(q15;q22), t(11;19)(q23;p13),-17,19p; der(19)t(17;19)(q11;p11), t(11;12)(p15;q13), NPM(-), FLT3(-)
  19                42        F            AML-M1                   Right inguinal area            Found at initial presentation with BM (+)                       Normal
  20                4         M            AML-M2                   Bone (left tibia)              Relapse after BMT, BM also (+)                                  t(8;21), AML1-ETO fusion transcription (+)
                                                                    Left buccal mucosa             Relapse after BMT, BM also (+)                                   
                                                                    Bone (right foot)              Relapse after BMT, BM also (+)                                   

*Abbreviations:* AML = acute myeloid leukemia; BM = bone marrow; BMT = bone marrow transplant; CML = chronic myeloid leukemia; FLT3 = FMS-like tyrosine kinase 3; MDS = myelodysplastic syndrome; NPM = nucleophosmin; RAEB = refractory anemia with excess blasts.

In our study, most irradiated MS lesions (17 lesions, 39.5%) were from patients with extramedullary relapse following BMT, and 10 (23.3%) lesions were from patients with BM relapse accompanied by extramedullary relapse. Seven (16.3%) lesions emerged following chemotherapy for underlying BM disease. Three (7%) lesions presented at diagnosis of hematological malignancy with BM involvement, 3 (7%) lesions presented during CML blast crisis, one (2.3%) lesion emerged during induction/consolidation chemotherapy and was persistent after BMT with positive BM disease, and one (2.3%) lesion presented as de novo sarcoma as the sole site without underlying BM disease. Of the 20 patients, 10 (50%) had normal cytogenetics and 10 (50%) displayed abnormal chromosomes, among which t(8;21)(q22;q22) was the most common abnormality (in 3 (30%) of 10 patients). Other observed abnormal cytogenetics included t(2;14), t(9;22), and del(15)(q22q35). Three patients displayed other chromosome complex changes: del(1)(p32p36), t(10;11)(p13;q13) in one patient, -3p, t(5:17)(q15;q22), t(11:19)(q23;p13), -17, +19p; der(19)t(17;19)(q11;p11), t(11;12)(p15;q13) in one patient, and 47 XXY with inv(11) in one patient.

Of the 20 patients, 9 survived and 11 died. The median survival time following RT was 6 months (range, 0.5-57 month) in all patients and 6.7 months (range, 2--57 month) in the surviving patients. The post-RT 1-year OS was 24% (Figure  [1](#F1){ref-type="fig"}).

![Kaplan-Meier overall survival curve for patients who received RT (radiotherapy) for MS (post RT survival rate).](1748-717X-8-245-1){#F1}

Correlations between RT responses and clinical characteristics
--------------------------------------------------------------

When evaluating the RT responses of the 20 patients with MS, we identified 13 patients (65%) with CR, 5 (25%) with PR, and 2 (10%) with SD. Totally, 19 (95%) of 20 patients achieved symptoms relief of MS after RT, except one patient with SD had persistent symptoms. Among patients with symptoms relief, 6 patients achieved symptoms relief during the treatment and 13 patients achieved symptoms relief within 3 months after completion of RT. Table  [2](#T2){ref-type="table"} displays the correlations between the patients' RT responses and their clinical characteristics. The rate of CR after RT and BED2 (≥22 Gy vs. \<22 Gy), underlying hematologic diseases (non-AML vs AML), sex, cytogenetics (normal vs abnormal), and BM status at the time of RT for MS (BM relapse vs BM remission) showed no significant correlations. Patients younger than 50 years of age had a marginally higher CR rate than those aged 50 years or older (83.3% vs. 37.6%, *P* = 0.06). Similarly, patients receiving BMT prior to RT had a marginally higher CR rate that those without previous BMT (100% vs. 50%, *P* = 0.05).

###### 

Predictive factors associated with clinical CR to radiotherapy (n = 20)

  **Characteristics**       **Complete response (No. of patients)**   **Partial response and stable disease (No. of patients)**   **Complete response rate**   **Crude odds ratio**   **95% Confidence interval**   ***P-value\****
  ------------------------- ----------------------------------------- ----------------------------------------------------------- ---------------------------- ---------------------- ----------------------------- -----------------
  BED dose                                                                                                                                                                                                           
  ≥22 Gy                    3                                         4                                                           43%                          4.44                   0.62-32.07                    0.14
  \<22 Gy                   10                                        3                                                           77%                          1 (Referent)                                          
  Underlying disease                                                                                                                                                                                                 
  Non-AML                   3                                         4                                                           43%                          4.44                   0.62-32.07                    0.17
  AML                       10                                        3                                                           77%                          1 (Referent)                                          
  Age                                                                                                                                                                                                                
  ≥50 y                     3                                         5                                                           37.5%                        8.33                   1.03-67.14                    0.06
  \<50 y                    10                                        2                                                           83.3%                        1 (Referent)                                          
  Gender                                                                                                                                                                                                             
  Female                    5                                         4                                                           55.6%                        2.13                   0.33-13.81                    0.64
  Male                      8                                         3                                                           72.7%                        1 (Referent)                                          
  Cytogenetics                                                                                                                                                                                                       
  Abnormal                  6                                         4                                                           60%                          1.56                   0.24-9.91                     1
  Normal                    7                                         3                                                           70%                          1 (Referent)                                          
  Previous BMT before RT                                                                                                                                                                                             
  Yes                       6                                         0                                                           100%                         NA                     NA                            0.05
  No                        7                                         7                                                           50%                          1 (Referent)                                          
  BM involvement at GS RT                                                                                                                                                                                            
  Yes                       8                                         5                                                           61.5%                        1.56                   0.22-11.37                    1
  No                        5                                         2                                                           71%                          1 (Referent)                                          

*Abbreviations:* CR, complete remission; PR, partial response; SD, stable disease, BMT, bone marrow transplant; RT, radiotherapy; BM, bone marrow.

\*Fisher's exact test.

When using the GEE model to analyze all 43 irradiated lesions, we observed that BED2, age, sex, cytogenetics, and bone marrow status at the time of RT for MS showed no significant associations with CR (Table  [3](#T3){ref-type="table"}). Patients with AML had a trend toward higher CR rate than those with non-AML (OR = 5.436, 95% CI = 0.999-29.578, *P =* 0.05). According to the logistic regression model, BMT prior to RT was also associated with marginally significant increased rate of CR following RT (OR = 0.099, 95% CI = 0.0086-1.135, *P =* 0.06).

###### 

Predictive factors associated with clinical complete remission to radiotherapy (43 lesions analyzed using the GEE model)

  **Characteristics**       **Complete response (No. of patients)**   **Partial response and stable disease (No. of patients)**   **Complete response rate**   **Univariate odds ratio**   **95% Confidence interval**   ***P-value***
  ------------------------- ----------------------------------------- ----------------------------------------------------------- ---------------------------- --------------------------- ----------------------------- ---------------
  BED dose                                                                                                                                                                                                                
  ≥22 Gy                    6                                         4                                                           60%                          1.15                        0.20-6.63                     0.88
  \<22 Gy                   21                                        12                                                          63.64%                       1 (Referent)                                               
  Underlying disease                                                                                                                                                                                                      
  Non-AML                   3                                         6                                                           33.33%                       5.436                       0.999-29.578                  0.050
  AML                       24                                        10                                                          70.59%                       1 (Referent)                                               
  Age                                                                                                                                                                                                                     
  ≥50 y                     9                                         5                                                           64.29%                       2.92                        0.47-18.14                    0.25
  \<50 y                    18                                        11                                                          62.07%                       1 (Referent)                                               
  Gender                                                                                                                                                                                                                  
  Female                    7                                         5                                                           58.33%                       1.41                        0.31-6.36                     0.65
  Male                      20                                        11                                                          64.52%                       1 (Referent)                                               
  Cytogenetics                                                                                                                                                                                                            
  Abnormal                  13                                        10                                                          56.52%                       1.35                        0.27-6.83                     0.72
  Normal                    14                                        6                                                           70%                          1 (Referent)                                               
  Previous BMT before RT                                                                                                                                                                                                  
  Yes                       16                                        2                                                           88.89%                       0.10                        0.01-1.14                     0.06
  No                        11                                        14                                                          44%                          1 (Referent)                                               
  BM involvement at GS RT                                                                                                                                                                                                 
  Yes                       16                                        8                                                           66.67%                       1.51                        0.23-9.82                     0.67
  No                        11                                        8                                                           57.89%                       1 (Referent)                                               

*Abbreviations:* CR, complete remission; PR, partial response; SD, stable disease; RT, radiotherapy; BMT, bone marrow transplant; BM, bone marrow.

Clinicopathologic features and survival of MS patients without RT
-----------------------------------------------------------------

Eighteen MS patients without RT served as control group. There were 10 (55.6%) men and 8 (44.4%) women with a median age of 17 years (range, 1--70 years) at diagnosis. The underlying hematologic diseases included AML in 14 (77.8%) patients, CML in 4 (22.2%) patients. The MS lesions included 5 (27.8%) skin, 4 (22.2%) bone, 2 (11.1%) orbital cavity, 1 (5.6%) brain, 1 (5.6%) breast, 1 (5.6%) cervix, 1 (5.6%) neck lymph node, 1 (5.6%) oral cavity, 1 (5.6%) ovary, and 1 (5.6%) uterus. Of the 18 patients, 9 (50%) had normal cytogenetics and 9 (50%) displayed abnormal chromosomes, among which t(9;22) (in 4 (22.2%) of 9 patients) and t(8;21)(q22;q22) (in 2 (11.1%) of 9 patients) were the common abnormality. Other observed abnormal cytogenetics included: t(9;11) in one patient, inv(7)(q22q36) in one patient, and del(7)(q32q36),del(18)(q21q23) in the other patient.

Treatments consisted of surgery alone in 1 (5.6%) patient, chemotherapy alone in 12 (66.4%) patients, a combination of surgery and chemotherapy in 2 (11.2%) patients, and bone marrow transplantation in 3 (16.8%) patients. CR was achieved in 16 (88.9%) of 18 patients and symptom relief was obtained in 17 (94.4%) of 18 patients. Of the 18 patients, 6 survived and 12 died. The median survival time was 8.5 months (range, 1--80 month) in all patients and 20.5 months (range, 6--80 month) in the surviving patients. The 1-year OS was 47.1%.

Discussion
==========

In this study, we evaluated clinicopathological features and treatment factors and their associations with RT responses in 20 patients with MS (in 43 RT courses), and also summarizes the clinicopathological features, cytogenetics, involved sites of MS, timing of RT, RT doses and fractions, and RT responses in published case reports (summarized in Table  [4](#T4){ref-type="table"}). Although our patients showed similar clinicopathologic features to those previously reported, we identified other diversified sites of MS involvement, including the breast \[[@B9]-[@B11]\], brain and spinal cord \[[@B12]-[@B15]\], cervix \[[@B16]-[@B19]\], paranasal sinus \[[@B20],[@B21]\], and oral cavity \[[@B22],[@B23]\]. We also observed previously unreported sites of involvement such as the nipple in men and the pituitary. Although the mechanism of MS formation is not fully understood, the leukemic cells homing to specific sites might be related to blast neural cell adhesion molecules (CD56) \[[@B2]\]. For example, high neural cell adhesion molecule expression in breast, testicular, ovarian, and gut tissue could explain these specific regions being common sites of MS involvement \[[@B24]\].

###### 

Published case reports on radiotherapy for GS

  **Study**                         **Patient no.**                   **Age**             **Cytogenetics**                                                               **Underlying disease**                                                    **Timing of GS emergence**                                                      **Radiotherapy site**                                                                                                                                                        **Dose fractionation**                  **Response**
  --------------------------------- --------------------------------- ------------------- ------------------------------------------------------------------------------ ------------------------------------------------------------------------- ------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------- ----------------------------------------------------------------------------------------
  Lee *et al*. \[[@B25]\]           1                                 50                  t(9;22)(q34;q11)                                                               CML                                                                       Relapse after BMT, BM (-)                                                       Clavicle and manubrium                                                                                                                                                       15 Gy                                   CR
  Taverna *et al.*\[[@B26]\]        1                                 62                  \-                                                                             AML-M4                                                                    Relapse after chemotherapy, BM also (+)                                         Left gluteal and the deeper pelvic muscles                                                                                                                                   20 Gy/10fx                              PR
  Au *et al.*\[[@B27]\]             1                                 24                  del( 5)(q13; q33)                                                              AML-M0                                                                    Relapse after BMT, BM (-)                                                       Left breast                                                                                                                                                                  30 Gy                                   PD
  Pulsoni *et al.*\[[@B28]\]        1                                 84                  \-                                                                             *De novo* sarcoma                                                         At presentation, BM (-)                                                         Skin                                                                                                                                                                         90 Gy/8fx                               CR
  Kasahara *et al.*\[[@B29]\]       1                                 47                  der (1; 7)(q10; p 10)                                                          Idiopathic myelofibrosis and *de novo* sarcoma                            At presentation, BM (-)                                                         Right submandibular tumor                                                                                                                                                    30 Gy                                   CR
  Buckland *et al.*\[[@B30]\]       1                                 35                  Normal karyotype                                                               *De novo* sarcoma                                                         At presentation, BM (-)                                                         C4-6 spine                                                                                                                                                                   32 Gy/16fx                              CR
  Lee *at al.*\[[@B31]\]            1                                 43                  \-                                                                             *De novo* sarcoma                                                         At presentation, BM (-)                                                         Maxillary gingiva                                                                                                                                                            36 Gy                                   CR
  Fleckenstein *et al.*\[[@B32]\]   1                                 73                  Normal karyotype                                                               AML                                                                       Found at initial presentation with BM (+)                                       Bilateral retrobulbar tumor                                                                                                                                                  30 Gy/15fx                              CR
  Cozzi *et al.*\[[@B33]\]          1                                 39                  Philadelphia positive                                                          CML                                                                       Chronic phase                                                                   Left shoulder                                                                                                                                                                21 Gy                                   PD
  Nishimura *et al.*\[[@B34]\]      1                                 30                  Add(3)(q27), t(8;21)(q22,q22)                                                  AML-M2                                                                    Relapse after BMT, BM (-)                                                       Right frontal intra/extracranial tumor                                                                                                                                       16 Gy                                   CR
  Pelosini *et al.*\[[@B35]\]       1                                 25                  t(8,21)with AML1-ETO expression.                                               AML-M0                                                                    Relapse after BMT, BM (-)                                                       Left leg                                                                                                                                                                     40 Gy                                   CR
  Rosenberg *et al.*\[[@B36]\]      1                                 8                   del(7)(q22;q36),t(7;11)(p15;p15)                                               AML-M2                                                                    Relapse after BMT, BM also (+)                                                  Bilateral synchronous epibulbar tumor                                                                                                                                        24 Gy/12fx                              CR
  Pitz *et al.*\[[@B37]\]           1                                 50                  Normal karyotype                                                               AML                                                                       Relapse after chemotherapy, BM also (+)                                         Uterus/ endometrium                                                                                                                                                          30 Gy/10fx                              CR
  Kumar *et al.*\[[@B38]\]          1                                 10                  \-                                                                             *De novo* sarcoma                                                         At presentation, BM (-)                                                         Left orbit                                                                                                                                                                   24 Gy/12fx                              CR
  Vassiliou *et al.*\[[@B39]\]      1                                 40                  \-                                                                             *De novo* sarcoma                                                         At presentation, BM (-)                                                         Mediastinal lymph node                                                                                                                                                       41.4 Gy/23fx                            CR
  Kozelj *et al.*\[[@B40]\]         1                                 52                  t(8;21)                                                                        AML                                                                       At presentation, BM (+)                                                         Heart                                                                                                                                                                        15 Gy/10fx                              CR
  Lee *et al.*\[[@B41]\]            1                                 25                  45,X,-Y,del(2)(q21q31),t(5;11)(q31;q13),t(8;21)(q22;q22),t(10;19)(q22;q13.1)   *De novo* sarcoma                                                         At presentation, BM (-)                                                         Orbit                                                                                                                                                                        70 Gy                                   PR
  Mauermann *et al.*\[[@B42]\]      1                                 70                  Normal karyotype                                                               *De novo* sarcoma                                                         At presentation, BM (-)                                                         Base of the skull to the upper thoracic region, including the brachial plexus                                                                                                20 Gy/10fx                              Good PR
  Verra *et al*. \[[@B43]\]         1                                 45                  inv(16)                                                                        AML-M4                                                                    Relapse after BMT, BM (-)                                                       L4 to S3 spine                                                                                                                                                               21 Gy/7fx                               PR
  Antic *et al.*\[[@B44]\]          1                                 24                  Normal karyotype                                                               *De novo* sarcoma                                                         At presentation, BM (-)                                                         Lumbosacral spine                                                                                                                                                            40 Gy/20fx                              CR
  Mignano *et al.*\[[@B45]\]        1                                 20                  \-                                                                             AML-M2                                                                    Relapse after BMT, BM (-)                                                       Left jaw                                                                                                                                                                     30 Gy/15fx                              CR
                                                                                                                                                                                                                                                                                                                                   Heart                                                                                                                                                                        24 Gy/12fx                              CR
  Kim *et al.*\[[@B16]\]            1                                 30                  \-                                                                             *De novo* sarcoma                                                         At presentation, BM (-)                                                         Uterus/cervix                                                                                                                                                                30 Gy                                   CR
  Alvarez *et al.*\[[@B46]\]        1                                 41                  CBFβ/MYH11 fusion and inv(16) (p13q22)                                         AML-M2                                                                    At initial presentation, BM also (+)                                            Small bowel, greater omentum and peritoneum                                                                                                                                  22.4 Gy/14fx                            CR
  Masetti *et al.*\[[@B47]\]        1                                 11                  11q23 rearrangement (*MLL*-*AF10*)                                             AML-M5                                                                    In remission after allogeneic hematopoietic stem cell transplantation, BM (-)   L1 to S3 Epidural mass                                                                                                                                                       20 Gy/16fx                              Good PR at the end of RT
  Chak *et al.*\[[@B5]\]            33 (54 courses of radiotherapy)   1.5 - 8 1           \-                                                                             28 (84.8%) acute non-lymphocytic leukemia, 11 (15.2%) chronic leukiemia   \-                                                                              33% bone, 31% soft tissue, 11% lymph node, 7% spinal cord, 6% brain, 11% other sites (Mediastinal mass, 2; pelvic mass, 1; pleural mass, 1 ; spleen, 1 ; porta hepatis, I)                                           \<1000 rad, CR 18%, 1000--1999 rad, CR 43%; 2000--2900 rad, CR 86%; \>3000 rad, CR 89%
  Bakst *et al.*\[[@B9]\]           22 (33 courses of radiotherapy)   Median 34 (1--71)   \-                                                                             AML 19 (86%), MDS 2 (9%), Isolated Chloroma 1 (5%)                        32% in remission (43% of them have GS concomitantly with marrow relapse)        39% head and neck, 24% extremity, 9% spine, 9% brain, 6% genito-urinary, 6% breast, 3% pelvis, and 3% genitourinary                                                          Median 20 (6--36) Gy/2 Gy (1.5--4 Gy)   CR 97%

*Abbreviations:* BM = bone marrow; CR = complete response; fx = fraction; Gy = gray; PD = progressive disease; PR = partial response.

In our cytogenetically abnormal patients, t(8;21)(q22;q22) was the most common cytogenetic change \[[@B48]\]. Limited previous reports exist on our identified cytogenetic abnormalities of t(2;14), t(9;22), and del(15)(q22q35) \[[@B11]\]. Systemic treatment outcome might be distinct among different cytogenetic groups. For example, in the study by Rollig et al., patients with t(8;21)(q22;q22) had good outcome following systemic treatment \[[@B49]\]. In our study, most patients had underlying AML disease. Of the non-AML patients, most had CML and a few had de novo sarcoma and MDS. In GEE analysis, we observed a trend that AML patients displayed higher CR rates than non-AML patients, which suggested that the underlying tumor behavior and biology of MS resulting from underlying diseases might differ. Further investigation to evaluate the radiobiological effects and elucidate the differential radiosensitivities of MS resulting from each underlying hematologic disease is warranted.

Another of our study findings was that BMT prior to RT resulted in marginally significant improvement of the CR rate in MS patients; however, the precise mechanism for the differential effects of RT on MS pre- and post-BMT are not well-understood. The incidence of patients developing MS after BMT is reportedly 0.2%-3.7% \[[@B50]-[@B52]\]. Myeloablative conditioning regimens of BMT often include high-dose busulfan/cyclophosphamide or cyclophosphamide in combination with total body irradiation. In allogeneic BMT, graft versus host interaction is an important factor in determining the success or toxicity of the transplant. Preclinical studies have demonstrated that radiation is involved in the recruitment of effector CD8+ T cells to nonlymphoid tissues and this effect enhances the graft-versus-leukemia (GVL) effect after allogeneic transplantation \[[@B53],[@B54]\]. These findings may explain that the more favorable response of MS toward RT after bone marrow transplant might be resulted from RT-inducing GVL effect. The influences of marked immununological disturbance during transplantation and graft versus host/leukemia interaction on the effects of RT (which is highly dependent on immunological interactions among the tumor, normal cells, and tumor microenvironment) warrant further investigation.

Age is considered a prognostic factor in AML. In our study, patients younger than 50 years of age had a trend toward higher CR rates following RT than those aged 50 years or older (83.3% vs 37.6%, *P* = 0.06). Kantarjian et al. reported reduced anthracycline sensitivity and Ras, Src, and tumor necrosis factor pathway activation in older patients with AML \[[@B55]\]. These deregulated signaling pathway variations may explain the poor response to RT in older patients with MS.

Although RT generally yields high CR rate, the optimal dose for MS has yet to be determined. Chak et al. \[[@B5]\] investigated the relationship between RT dose and response in 33 MS patients (54 RT courses), observing that the CR rate was closely associated with RT dose (CR rate: \<10 Gy, 18%; 10--19.99 Gy, 43%; 20--29.99 Gy, 86%; \>30 Gy, 89%). In their study on 22 patients with MS (33 RT courses) who received a median dose of 20 Gy (range 6--36 Gy) in fractions of 1.5-4 Gy, Bakst et al. showed that RT resulted in excellent disease control and minimal morbidity \[[@B9]\]. The authors recommended a low-dose regimen of 24 Gy in 12 fractions to irradiate MS. Our findings are consistent with the two mentioned large series reports, and demonstrate excellent local control in our 20 MS patients (43 RT courses), who received a median dose of 20 Gy (range 6--35 Gy) in fractions of 1.5-3.5 Gy. Although our results indicated that BED2 had nonsignificant effects on CR rate (≥22 Gy vs \<22 Gy), most previous cases series have reported good local control of MS in low to moderate RT doses between 20 Gy and 30 Gy (Table  [4](#T4){ref-type="table"}). The main mechanism of radiation damage to leukemic cells is apoptosis. For high-dose irradiation, the D~0~ of p53-deficient HL-60 leukemic cells is 2.2 Gy, and the D~0~ of p53 wild MOLT-4 leukemic cells is 0.87 Gy \[[@B56]\]. According to radiobiological and clinical data, a 20--30 Gy radiation dose might be sufficient to achieve good local control for MS \[[@B57]\].

Conclusion
==========

In summary, in this study, we evaluated the clinicopathological features and radiotherapeutic responses of 20 MS patients with 43 lesions, and identified unusual sites of MS presentation, including the nipple in men and the pituitary. Diversified cytogenetic abnormalities can occur in MS; however, the most common MS-associated cytogenetic change is t(8;21)(q22;q22). We further identified that the CR rate is optimal using moderate RT doses between 20 Gy and 30 Gy with conventional fractionation. Younger age, BMT prior to RT, and AML patients had marginally significant trend toward higher CR rate in MS.
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